Related Experiment Video

Updated: Jun 5, 2026

Contractions of Human-iPSC-derived Cardiomyocyte Syncytia Measured with a Ca-sensitive Fluorescent Dye in Temperature-controlled 384-well Plates
07:42

Contractions of Human-iPSC-derived Cardiomyocyte Syncytia Measured with a Ca-sensitive Fluorescent Dye in Temperature-controlled 384-well Plates

Published on: October 18, 2018

Selecting a calcium channel-blocking agent

E Gutman

    Canadian Family Physician Medecin De Famille Canadien
    |January 26, 2011
    PubMed

    Insights

    Calcium channel blockers like nifedipine, diltiazem, and verapamil treat cardiovascular disorders. Despite a shared mechanism, their distinct properties necessitate careful selection for patient-specific needs.

    Area of Science:

    • Pharmacology
    • Cardiovascular Medicine

    Background:

    • Nifedipine, diltiazem, and verapamil are key channel-blocking agents.
    • These drugs are vital for managing cardiovascular disorders, particularly ischemic heart disease.

    Purpose of the Study:

    • To differentiate the cardiovascular effects and pharmacological properties of nifedipine, diltiazem, and verapamil.
    • To highlight the specific clinical indications for each channel-blocking agent.
    • To guide physicians in selecting the optimal drug based on patient needs.

    Main Methods:

    • Comparative analysis of pharmacological profiles.
    • Review of clinical indications and patient outcomes.

    Main Results:

    • Significant differences exist in the cardiovascular effects and pharmacological properties among the three agents.
    • Each drug possesses unique clinical indications, limiting interchangeability.

    Conclusions:

    • Understanding the distinct properties of nifedipine, diltiazem, and verapamil is crucial.
    • Physicians must carefully select the appropriate channel blocker for individual patient requirements to optimize treatment outcomes.

    More Related Videos

    High-Throughput Optical Controlling and Recording Calcium Signal in iPSC-Derived Cardiomyocytes for Toxicity Testing and Phenotypic Drug Screening10:01

    High-Throughput Optical Controlling and Recording Calcium Signal in iPSC-Derived Cardiomyocytes for Toxicity Testing and Phenotypic Drug Screening

    Published on: March 31, 2022

    Related Concept Videos

    Antihypertensive Drugs: Action of Calcium Channel Blockers01:18

    Antihypertensive Drugs: Action of Calcium Channel Blockers

    Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
    Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

    Antianginal Drugs: Calcium Channel Blockers and Ranolazine

    Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
    CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
    Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

    Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

    Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
    Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
    Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

    Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

    Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
    Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
    Antiepileptic Drugs: Calcium Channel Blockers01:17

    Antiepileptic Drugs: Calcium Channel Blockers

    Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
    Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
    Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

    Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

    Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...